Previsioni

Il prezzo obiettivo medio degli analisti è 19,42 € (+72,16%). La mediana è 19,42 € (+72,16%).

Acquista	9
Mantieni	1
Vendi	0

Notizie Vai al feed delle notizie

Candel Therapeutics hits 52-week high at $13.96 and launches phase‑III AURORA study

Candel Therapeutics’ stock rose to a 52‑week high of $13.96 and is currently trading around $13.93, implying a market capitalization of about $1.06 billion. The shares have gained substantially year‑to‑date (roughly +125–132% according to data), and InvestingPro sees the stock near its fair value. Candel has initiated the global phase‑III AURORA study of aglatimagene besadenovec in metastatic non‑small cell lung cancer; analysts raised price targets and reiterated buy ratings. Mark Sims was also appointed chief commercial officer; the company is targeting a Biologics License Application submission for the therapy by the end of 2026. » Altro su de.investing.com
Candel Therapeutics: positive phase‑3 data on aglatimagene besadenovec and launch of AURORA study

Candel Therapeutics reports pivotal phase‑3 PrTK03 data showing a significant improvement in disease‑free survival for aglatimagene besadenovec in localized prostate cancer. In parallel, the phase‑3 AURORA study was launched. Stifel initiated coverage of the stock with a 'Buy' rating and a $22 price target. » Altro su finanzen.net
Candel strikes commercialization partnership with Eversana for prostate cancer drug

Candel has agreed a product commercialization deal with Eversana to support the potential U.S. launch of aglatimagene besadenovec. Eversana will provide data analytics, medical affairs, market access and field support; a BLA filing is planned for Q4 2026. According to analysis, Candel has more cash than debt and is continuing to prepare for regulatory review; aglatimagene has Fast Track and RMAT designations but is not yet approved. Analyst consensus is "Strong Buy" with price targets of $7 to $26, the stock was volatile last week and is currently trading at $6.20. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, CANDEL THERAP.INC. DL-,01 ha registrato ricavi pari a 0 € e un utile netto di -34,09 Mln €

(EUR)	giu 2026	YoY
Ricavi	0	-
Utile lordo	0	-
Utile netto	-34,09 Mln	737,77%
EBITDA	-32,43 Mln	785,18%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	881,56 Mln €
Numero di azioni	73,27 Mln
Massimo/minimo a 52 settimane	12,08 € - 3,75 €
Dividendi	No
Beta	-0,50
Rapporto P/E	-9,89
Rapporto PEG	0,12
Rapporto P/B	8,19
Rapporto P/S	0,00

Profilo aziendale

Candel Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Phase und beschäftigt sich mit der Entwicklung von Immuntherapien für Krebspatienten. Das Unternehmen entwickelt CAN-2409, das sich in klinischen Studien der Phase II zur Behandlung von Bauchspeicheldrüsenkrebs, in klinischen Studien der Phase III zur Behandlung von Prostatakrebs und in klinischen Studien der Phase II zur Behandlung von Lungenkrebs befindet, und hat klinische Studien der Phase Ib/II zur Behandlung von hochgradigen Gliomen abgeschlossen. Das Unternehmen entwickelt außerdem CAN-3110, das sich in klinischen Studien der Phase I zur Behandlung des rezidivierenden Glioblastoms befindet. Das Unternehmen war früher als Advantagene, Inc. bekannt und änderte im November 2020 seinen Namen in Candel Therapeutics, Inc. Das Unternehmen wurde im Jahr 2003 gegründet und hat seinen Sitz in Needham, Massachusetts.

Nome	CANDEL THERAP.INC. DL-,01
CEO	Paul-Peter Tak
Sede centrale	Needham, ma Stati Uniti
Sito web	candeltx.com
Settore	Beni di prima necessità
Industria	Prodotti alimentari
Quotazione in borsa	27/07/2021
Dipendenti	55